Fujifilm Demonstrates Meaningful Use Stage II Requirements for Radiology Professionals at RSNA 2013

  Fujifilm Demonstrates Meaningful Use Stage II Requirements for Radiology
  Professionals at RSNA 2013

RSNA 2013

Business Wire

STAMFORD, Conn. -- December 1, 2013

(Booth #2539 South Building) – FUJIFILM Medical Systems U.S.A., Inc., will
offer the latest version of Synapse RIS, a complete electronic health record
(EHR)-certified solution that can be quickly and easily adapted to meet
Meaningful Use (MU) Stage II requirements for radiology professionals at the
99th annual meeting of the Radiological Society of North America (RSNA) in
Chicago, IL.

Synapse RIS, a complete electronic health record (EHR)-certified solution that
can be quickly and ea ...

Synapse RIS, a complete electronic health record (EHR)-certified solution that
can be quickly and easily adapted to meet Meaningful Use (MU) Stage II
requirements for radiology professionals. (Photo: Business Wire)

“Synapse RIS has integrated EHR into a powerful radiology management tool that
can enhance workflow and increase the productivity of radiology practices,”
said Jim Morgan, vice president of Medical Informatics, FUJIFILM Medical
Systems U.S.A., Inc. “The platform offers the flexibility needed to support
additional stages of meaningful use criteria, as well as other government
regulations that may be forthcoming.”

Customers can count on continual innovation and comprehensive services
provided by Fujifilm. Synapse RIS integrates seamlessly with Synapse PACS and
has additional productivity enhancing features for radiologists such as:

  *An interactive analytics dashboard that provides a visual snapshot of key
    performance indicators
  *Peer review capabilities directly integrated into the diagnostic process
  *Urgent findings for providing closed-loop communications and compliance
  *Patient portal capabilities to empower patients, reduce wait times and
    satisfy meaningful use criteria

Integration with ACR Select allows practices to obtain guidance as to the most
appropriate imaging procedure at CPOE and at Point of Schedule. This improves
the overall quality of care by ensuring patients get the proper imaging
procedure, and the order is based on a structured reason for exam.

The Meaningful Use initiative provides incentive payments to eligible
professionals (EPs) who use a certified complete EHR solution in a meaningful
way. The American College of Radiologists has projected that 90% of
radiologists can qualify for EHR. In the Stage 1 meaningful use regulations,
CMS had established a timeline that required providers to progress to Stage 2
criteria after two years under the Stage 1 criteria. This timeline would
require Medicare providers who first demonstrated meaningful use in 2011 to
meet the Stage 2 criteria in 2014.

To register for a product demonstration at RSNA, please visit
http://rsna.fujimed.com. For every product demonstration registered online,
Fujiflim will donate $25 to the National Breast Cancer Foundation. For more
information about Synapse RIS, please visit: http://www.synapseris.com/

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic
imaging products and medical informatics solutions to meet the needs of
healthcare facilities today and well into the future. From an unrivaled
selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and
cardiovascular products, to advanced women’s health imaging systems, Fujifilm
has products that are ideal for any size imaging environment. The Endoscopy
Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality,
technologically advanced FUJINON brand endoscopes to the medical market.
FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For
more information, please visit www.fujimed.com and www.fujifilmendoscopy.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and
leading-edge products to a broad spectrum of industries, including electronic
imaging, digital printing equipment, medical systems, life sciences, graphic
arts, flat panel display materials, and office products, based on a vast
portfolio of digital, optical, fine chemical and thin film coating
technologies. The company was among the top 10 companies around the world
granted U.S. patents in 2012, and in the year ended March 31, 2013, had global
revenues of $26.7 billion*. Fujifilm is committed to environmental stewardship
and good corporate citizenship. For more information, please visit
www.fujifilmholdings.com.

* At an exchange rate of 83 yen to the dollar.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131201005023/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50759408&lang=en

Contact:

Fujifilm
Lauren Geloso, 914-789-8303
lgeloso@fujifilm.com
 
Press spacebar to pause and continue. Press esc to stop.